The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
March 27, 2014
- Qualified Bidders Selected in 1st Qol-Led Open Tender
March 27, 2014
- PII Study of Anti-PCSK9 Antibody in Japanese Patients Meets Primary Endpoint: Amgen Astellas
March 27, 2014
- Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
- DSP’s Antipsychotic Agent Latuda Gets OK in Australia
March 26, 2014
- MHLW Approves Toyama Chemical’s Novel Anti-Influenza Drug Avigan Tablets
March 26, 2014
- Mitsui Becomes Largest Shareholder of Fuji Pharma through Capital, Business Alliance
March 26, 2014
- Otsuka’s Samsca Approved in Japan as World’s 1st ADPKD Treatment
March 26, 2014
- Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
- EU Panel Backs Approval of Takeda’s Vedolizumab
March 25, 2014
- Sanofi Now Reconciled with All 3 Generic Makers over Allegra Patent
March 25, 2014
- Chugai to Join High-Quality Protein Crystal Growth Experiment in Kibo Space Lab
March 24, 2014
- OrphanPacific Voluntarily Recalls Buphenyl Tablets
March 24, 2014
- Hospira Voluntarily Recalls 9 Generic Anticancer Agents Due to Incomplete Labeling
March 24, 2014
- Maruho Files NDA for Acne Drug in Japan
March 20, 2014
- Astellas Seeks US Approval for Additional Indication of Enzalutamide
March 20, 2014
- Astellas, Daiichi Sankyo Hook Up in Compound Library Sharing
March 20, 2014
- Galderma Files NDA for Cancer Odor Treatment
March 20, 2014
- Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
- Sanofi Settles Allegra Generic Suit with Elmed Eisai, Kobayashi Kako
March 19, 2014
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…